Definitive Contract HHSN261201200074C
Award Date 9/20/12
Potential Completion Date 8/23/13
Potential Value $199K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Needham, MA 02494, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
18
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Celartia, Inc., a small disadvantaged business, for the development of a fully automated system for cell therapy processing. The contract has a period of performance from September 13, 2021 to June 12, 2022 and a ceiling value of $393,312. The contract was awarded under a total small business set-aside. The original...
- <p>This is a $199,969 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Accelerated Medical Diagnostics, Inc. The contract is for "OTHER FUNCTIONS - R & D BIOMEDICAL (BASIC RESEARCH)" and has a firm fixed price pricing type with a completion date of September 30, 2016. As an SBIR Phase I award, this contract supports early-stage research and development activities.</p>
- <p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. government. The contract, valued at $1,499,398.79, was awarded to Siamab Therapeutics, Inc. to develop novel therapeutic agents that target cancer stem cells, as described in SBIR Topic 326. The contract has a period of performance through September 18, 2018 and is a Cost Plus Fixed Fee definitive contract.</p>
- <p>This is a $1,496,276.00 Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a civilian agency, to Cellerant Therapeutics, Inc. The contract is for the SBIR (Small Business Innovation Research) Phase II development of novel therapeutic agents that target cancer stem cells, under Topic 326. The contract has a total small business set-aside designation and was awarded on September 19, 2016 with an ultimate completion date of April 16, 2018.</p>
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanotarget LLC for the development of a nanoparticle CD8 T cell regimen for cancer therapy. The firm-fixed-price contract has a ceiling value of $174,251 and a period of performance ending on May 31, 2010. No subcontractors are mentioned. The SBIR program supports research and development of innovative technologies by small businesses to address key...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Myelorx LLC, a for-profit limited liability company. The contract has a total potential value of $1,917,332.00 and was awarded on September 30, 2009, with a period of performance ending on December 12, 2013. The contract is for research under SBIR Topic 255 and is designated as a total small business set-aside. No further details about the specific...
- This is a $200,000.00 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Nanomaterial Innovation LTD, a woman-owned limited liability company. The contract is for the development of "MULTIFUNCTIONAL SIRNA NANOPARTICLES FOR AML THERAPY", which aligns with NCI's research focus on cancer therapeutics. The contract has a firm fixed price pricing type and was awarded on September 24, 2010 with a...
- <p>The National Cancer Institute (NCI) awarded a $249,792 Small Business Innovation Research (SBIR) Phase I contract to Biotex, Inc. to develop "Instruments and Devices that Preserve Molecular Profiles in Tumors" under SBIR Topic 257. The contract is a firm-fixed-price definitive contract with a period of performance ending on June 30, 2010. This SBIR contract supports the NCI's research objectives related to advancing cancer diagnostics and therapeutics.</p>
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Biocure Inc. for the development of "Targeted Multifunctional Polymersomes for Cancer Therapy". The contract is a Firm Fixed Price Definitive Contract with a ceiling value of $199,889. The period of performance is from the award date of September 30, 2009 to the ultimate completion date of July 31, 2010. This SBIR Phase I contract is focused on...